HBI-002 is under clinical development by Hillhurst Biopharmaceuticals and currently in Phase I for Sickle Cell Disease. According to GlobalData, Phase I drugs for Sickle Cell Disease have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HBI-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HBI-002 overview
Carbon monoxide is under development for the treatment of pulmonary injury from viral infections, sickle cell disease, Parkinson's disease, cystic fibrosis, concussion (brain injury), ulcerative colitis, acute ischemic stroke, kidney transplant rejection and doxorubicin related cardiotoxicity. It is administered through oral route. The drug candidate acts by targeting heme oxygenase metabolic pathway. It was also under development for the treatment of multiple sclerosis.
Hillhurst Biopharmaceuticals overview
Hillhurst Biopharmaceuticals is a pharmaceutical company that develops novel liquid therapeutic solutions designed to treat patients with sickle cell disease. The company is headquartered in San Diego, California, the US.
For a complete picture of HBI-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
